Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications
admin 26th May 2017 Uncategorised 0The idiopathic pulmonary fibrosis market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since the FDA green-lighted the medications in October, 2014. And this week, both drugmakers upped the ante with positive new data for their contenders.
More: Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications
Source: fierce